CvergenX, NCI Partner on Radiation Therapy Prediction Assay | GenomeWeb

NEW YORK (GenomeWeb News) – With the help of the National Cancer Institute, CvergenX is developing a radiosensitivity test for use in determining how patients respond to radiation therapy, the company said late Tuesday.

NCI has chosen CvergenX's technology called InterveneXRT for further development and validation in a commercial collaboration in order to advance the assay for use in clinical trials and potentially approval by the US Food and Drug Administration. CvergenX is developing the technology in conjunction with NCI's Clinical Assay Development Program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This week in Nature: Researchers describe the adaptation of organisms to environmental changes, while another study provides new insights into pig domestication.

The blog Sartorial Science seeks to challenge the stereotype of scientists as frumpy, messy, clueless dressers.

While one researcher says cloning the mammoth may be decades away, if successful, it may lead to a theme park of species that would no longer be extinct.

DNA Sequencing is being used by researchers in California to survey fish and marine life as part of a conservation effort.